New insights for low dosing with the new P2Y12 inhibitors.
Institut de Cardiologie, Pitié-Salpêtrière University Hospital.
Johanne
J
Silvain
Mathieu
M
Kerneis
Jean Philippe
JP
Collet
Gilles
G
Montalescot
D003327:Coronary Disease / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D062645:Percutaneous Coronary Intervention; D010879:Piperazines / Q000627:therapeutic use*; D000068799:Prasugrel Hydrochloride; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*
D010879:Piperazines; D058921:Purinergic P2Y Receptor Antagonists; D013876:Thiophenes; D000068799:Prasugrel Hydrochloride